Open an account

Sionna Therapeutics

SION · NASDAQ

$4.15+$0.14 (+3.49%)TodayMarket closed ·
Prev close $4.01

About SION

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 59 full-time employees. The company went IPO on 2025-02-07. The firm is focused on researching and developing novel medicines for cystic fibrosis. The company is advancing a pipeline of small molecules engineered to correct the defects caused by the F508del genetic mutation, which resides in nucleotide-binding domain 1 (NBD1). The company is conducting ongoing Phase I trials of its two highly potent NBD1 stabilizers, SION-719 and SION-451, evaluating the safety, tolerability and pharmacokinetic (PK) profile of single and multiple ascending doses in healthy subjects. The company is also developing a portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) modulators designed to work synergistically with its NBD1 stabilizers to improve CFTR function. Its portfolio also includes Galicaftor (SION-2222) and SION-2851, which are TMD1-directed CFTR correctors; SION-109, an ICL4-directed CFTR corrector, and Navocaftor (SION-3067), is a clinical-stage potentiator of CFTR gating activity.

Employees
59
Headquarters
Waltham, Massachusetts
Listed
Feb 7, 2025
Sector
Health Care
Industry
Biotechnology
Website
sionnatx.com

SION key statistics

Market cap
187.63M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.20M
Volume
1.07M
Open price
$4.06
High today
$4.30
Low today
$4.02
52 Week high
$54.97
52 Week low
$3.78

Sionna Therapeutics (SION) at a glance

Sionna Therapeutics (SION) last traded at $4.15, with a market cap of 187.63M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $4.02 and $4.30. The current price is 3.2% above the day's low and 3.5% below its high.

Volume so far is 1.07M shares, in line with the average of 1.20M shares a day.

Over the past year Sionna Therapeutics has ranged from $3.78 to $54.97, and now sits 1% of the way up that range.

Sionna Therapeutics met or beat analyst EPS estimates in 4 of the last 7 quarters. In Q2 FY26 it reported -$0.66 per share against an estimate of -$0.6625.

The average analyst price target is $15.64, 276.9% above the current price, from 9 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

44%of 9 analyst ratings say Buy
  • Buy44.4%
  • Hold44.4%
  • Sell11.1%
Price target · 8 analystsAvg $15.64
Low
$5.05
Now
$4.15
High
$66.15

SION earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 7 quarters, by 12.8% on average.

  1. Q4 FY24: reported -$3.38 per share against an estimate of -$0.5865
  2. Q1 FY25: reported -$0.62 per share against an estimate of -$0.4565
  3. Q2 FY25: reported -$0.41 per share against an estimate of -$0.5661
  4. Q3 FY25: reported -$0.46 per share against an estimate of -$0.494
  5. Q4 FY25: reported -$0.46 per share against an estimate of -$0.5494
  6. Q1 FY26: reported -$0.60 per share against an estimate of -$0.5244
  7. Q2 FY26: reported -$0.66 per share against an estimate of -$0.6625

SION news

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

  • Press releasePRNewswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

  • Press releaseGlobe Newswire

    Sionna Therapeutics Announces Plans to Advance SION-451 + SION-2222 Dual Combination into Phase 2a Proof-of-Concept Trial

  • Press releaseGlobe Newswire

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sionna Therapeutics, Inc. - SION

  • Press releaseGlobe Newswire

    SIONNA THERAPEUTICS INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Sionna Therapeutics Inc on Behalf of Sionna Therapeutics Stockholders and Encourages Investors to Contact the Firm

  • Press releaseGlobe Newswire

    SION INVESTIGATION: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

  • Press releasePRNewswire

    INVESTIGATION ALERT: Investigation Launched into Sionna Therapeutics, Inc., Robbins Geller Rudman & Dowd LLP Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm - SION

Similar companies

Companies in the same industry as Sionna Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.